A Growing Burden, a Persistent Gap: Cannabinoid Hyperemesis Syndrome Education and Emergency Department Trends in Michigans Legal Cannabis Market
This study reveals a 57-fold increase in cannabinoid hyperemesis syndrome (CHS) emergency department visits in Kalamazoo, Michigan, following recreational legalization in 2018, while highlighting a critical absence of CHS warnings and educational content on licensed retailer and public health websites, prompting a recommendation to mandate specific CHS warnings in point-of-sale materials.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the United States, the landscape of cannabis has shifted dramatically in recent years, moving from a strictly regulated medical commodity to a widely available recreational product. As states legalize the sale of marijuana for adults, a specific and distressing medical condition has begun to appear with increasing frequency in emergency rooms. This condition, known as cannabinoid hyperemesis syndrome, affects people who use cannabis heavily and chronically. It is characterized by cycles of severe nausea, vomiting, and abdominal pain that can be so intense that patients feel compelled to take hot showers or baths to find temporary relief. While doctors have recognized this syndrome for some time, the rapid expansion of legal markets has raised a critical public health question: are consumers being warned about this risk before they buy the product, or are they learning about it only after they become sick?
A team of researchers in Kalamazoo, Michigan, set out to investigate this disconnect between the rising number of sick patients and the information available to the public. Michigan legalized recreational cannabis in late 2018, and the city of Kalamazoo, home to a major teaching hospital, became a focal point for observing the local impact. The researchers first looked at the medical records of a local hospital to see how many people had been treated for this specific syndrome before and after the law changed. They found a stark difference. Between 2010 and late 2018, the hospital recorded only six emergency department visits where the primary diagnosis was this syndrome. However, in the years following legalization, from late 2018 through the end of 2025, that number surged to 274 visits. The average patient was a young adult, roughly 29 years old, and the increase was so dramatic that the rate of visits after legalization was dozens of times higher than before.
Despite this sharp rise in patients arriving at the emergency room, the researchers then turned their attention to the sources where consumers typically learn about cannabis. They conducted a systematic search of the websites for every licensed cannabis retailer in Kalamazoo, as well as the websites for the local county health department and the state health agency. Their goal was to find any educational materials, warnings, or descriptions of the syndrome that a customer might see while shopping. The results revealed a significant gap in communication. Among the nineteen active cannabis businesses they reviewed, only one mentioned the syndrome at all, and even then, the information was buried deep within a digital booklet rather than displayed prominently on the main website. That single mention did not describe the symptoms or offer advice on when to seek medical help. The websites for the local and state health departments contained no information about the condition whatsoever.
The study suggests that while the clinical burden of the syndrome is growing rapidly, the consumer-facing education has not kept pace. The researchers noted that the current laws in Michigan require retailers to provide a pamphlet with safety information, but this requirement does not currently mandate specific warnings about this syndrome. Because the condition is often misdiagnosed or overlooked, patients may undergo extensive and costly medical testing to rule out other causes of their vomiting before the correct diagnosis is made. The authors argue that this lack of clear, accessible warning at the point of sale leaves consumers unaware of a serious potential side effect of heavy use. They conclude that to protect public health and reduce the strain on emergency departments, the existing rules for what information must be given to customers should be updated to include specific, clear warnings about this syndrome, ensuring that the people buying the product are also informed about its risks.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.